Ernexa Therapeutics (ERNAW) Net Cash Flow (2010 - 2026)

Ernexa Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 3739.68% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (up 199.34% YoY), and the FY2025 full-year result was $155000.0, up 101.56% from the prior year.
• Net Cash Flow for Q1 2026 stood at $7.3 million, up from -$1.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $7.3 million in Q1 2026, with the low at -$6.2 million in Q3 2022.
• Historically, Net Cash Flow has averaged -$460117.6 across 5 years, with a median of -$1.2 million in 2025.
• Annual changes were most pronounced in 2023 — Net Cash Flow slumped 192.85% — and 2026, when it jumped 3739.68%.
• Ernexa Therapeutics' Net Cash Flow stood at $2.3 million in 2022, then jumped by 32.23% to $3.0 million in 2023, then tumbled by 183.83% to -$2.5 million in 2024, then jumped by 54.12% to -$1.2 million in 2025, then surged by 723.99% to $7.3 million in 2026.
• The last three Net Cash Flow figures came in at $7.3 million (Q1 2026), -$1.2 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.